Cytokinetics (NASDAQ:CYTK) Upgraded by Morgan Stanley to Overweight Rating
Morgan Stanley upgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from an equal weight rating to an overweight rating in a research note issued to investors on Thursday morning,Benzinga reports. They currently have $67.00 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $70.00. CYTK has been the subject of […]
More Stories
Chinese Stocks To Follow Today – July 2nd
Duolingo, Wynn Resorts, Mettler-Toledo International, Diageo, and UP Fintech are the five Chinese stocks to watch today, according to MarketBeat’s...
Best Agriculture Stocks To Research – July 3rd
Chubb, Deere & Company, Norfolk Southern, CNH Industrial, Apollo Global Management, Steel Dynamics, and Arch Capital Group are the seven...
Best Penny Stocks To Watch Today – July 3rd
Wolfspeed, Bit Digital, and Global Interactive Technologies are the three Penny stocks to watch today, according to MarketBeat’s stock screener...
JPMorgan Chase & Co. Reaffirms Overweight Rating for The Sage Group (LON:SGE)
JPMorgan Chase & Co. reissued their overweight rating on shares of The Sage Group (LON:SGE – Free Report) in a...
JPMorgan Chase & Co. Reiterates Overweight Rating for Flutter Entertainment (LON:FLTR)
JPMorgan Chase & Co. reaffirmed their overweight rating on shares of Flutter Entertainment (LON:FLTR – Free Report) in a research...
Gore Street Energy Storage Fund (LON:GSF) Cut to “Underperform” at Royal Bank Of Canada
Royal Bank Of Canada lowered shares of Gore Street Energy Storage Fund (LON:GSF – Free Report) to an underperform rating...